MSLN and ovarian carcinoma: Tandem CAR-Ts targeting cancer-specific upregulated molecules mesothelin and folate receptor 1 (FOLR1) with secretory activity of IL-12 had higher infiltration and persistence comparative to anti-mesothelin CAR-Ts, and the secretion of IL-12 enhanced therapeutic effects and reduced tumor antigen escape in ovarian cancer [100].